THE US Food and Drug
Administration has approved Botox
injection (onabotulinumtoxinA)
therapy for the prevention of
headaches in adults suffering
chronic migraines (defined as
having a headache on most days
of the month).
To treat chronic migraines, Botox
is given approximately every 12
weeks as multiple injections
around the head and neck, to try
to dull future symptoms.
The FDA said Botox had not
been shown to work for the
treatment of migraine headaches
that occur 14 days or less per
month, or for other forms of
headache.The above article was sent to subscribers in Pharmacy Daily's issue from 19 Oct 10 To see the full newsletter, see the embedded issue below or CLICK HERE to download Pharmacy Daily from 19 Oct 10
THE stark health inequalities between Australians living in regional and metro areas have been highlighted in a new report from The Royal Flying Doctor Service (RFDS).
AN “AI explosion” is sweeping Australia’s healthcare sector, signalling the arrival of an “extraordinary era of medicine”, according to a new report from CSIRO.
THE Australian and New Zealand College of Advanced Pharmacy (ANZCAP) has celebrated the 1,000th pharmacist to complete its pharmacy recognition program (PD 24 Nov 2023).
FREE Pharmacy Daily subscription - never miss another story!
to top
Subscribe to Pharmacy Daily
Pharmacy Daily subscription confirmation
Thank you for signing up! Check your email inbox – you should shortly receive a message with a link which must be clicked to confirm your subscription.
Once you’ve done that you will begin receiving Pharmacy Daily as soon as the next issue is published.